drug-drug conjugate (DDC) platform — Initial data
Late 2026
Nuvation Bio continues to explore new preclinical candidates for this novel modality and aims to provide further updates by year-end 2026.Source filing
NUVB biotech catalysts & pipeline
NUVATION BIO INC · Data as of 2026-10-25
Upcoming catalysts
safusidenib — Clinical data readout
2027
Data is anticipated to be available in 2027.Source filing
IBTROZI (taletrectinib) — PDUFA
Jan 4
In May 2026, we announced the FDA had accepted a supplemental New Drug Application with updated data for IBTROZI in both TKI-naïve and TKI-pretreated advanced ROS1+ NSCLC with a target action date of January 4, 2027.Source filing
safusidenib — Clinical data readout
2029
Data is anticipated to be available in 2029.Source filing